Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of **ginseng + concha ostreae** (often referred to as the **Shen-Mu** formula) is a Traditional Chinese Medicine (TCM) therapy developed by the **Affiliated Hospital of Shandong University of TCM** for the management of cancer pain, particularly bone cancer pain. This formulation leverages the "Qi-tonifying" properties of *Panax ginseng* and the "sedative" and "astringent" effects of *Concha Ostreae* (oyster shell). Pharmacological research indicates that the combination exerts analgesic effects by modulating inflammatory pathways and pain-related signaling. Specifically, it has been shown to downregulate the expression of pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), while also inhibiting the transient receptor potential vanilloid 1 (TRPV1) channel and reducing levels of substance P in the spinal cord. It is typically administered orally as a decoction or granule preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginseng + concha ostreae.